Medical drugs
AstraZeneca beats sales and profit expectations on cancer drug demand
Core earnings for the three months ended March rise to US$2.58 per share, while total revenue jumps 8% to US$15.3 billion
China races to build record biobank to rival US drugs research
Beijing has equally begun to protect its own nascent databases, passing a biosecurity law in 2020
Trump will impose 100% tariff on some patented drugs
[WASHINGTON, DC] The Trump administration will impose tariffs of as much as 100 per cent on certain imported medicines, albeit with several major exemptions, a maneuver to pressure drugmakers to manuf...
Low-cost Ozempic copies launch in India as Novo Nordisk’s patent expires
One firm plans to make a semaglutide jab at a starting price of 1,290 rupees a month
Rethinking our global health architecture in a fragmented world
The international health governance landscape is at a critical and precarious juncture
Merck to create separate cancer business as Keytruda patent loss looms
This underscores the US drugmaker’s push to diversify beyond its blockbuster drug
India to spend 100 billion rupees to make biopharma production hub
The funding will be directed towards the research and production of biologics and biosimilar medicines
US FDA launches programme to boost domestic drug manufacturing
It’s in line with President Donald Trump’s executive order in May to shift manufacturing of drugs to the US
AstraZeneca strikes deal for up to US$18.5 billion to license weight-loss drugs from China's CSPC
The deal builds on existing collaboration between the companies in areas such as artificial intelligence
‘Treating obesity for the next 100 years’: Ozempic-maker Novo Nordisk targets tripling of Apac patient base
By sales volumes for its GLP-1 drugs, the company’s largest markets in the region are Australia, Japan, South Korea and India
